-
admin
Posts
ZKH Group Limited to Announce Second Quarter 2024 Financial Results on Thursday, August 22, 2024
SHANGHAI, Aug. 8, 2024 /PRNewswire/ — ZKH Group Limited (“ZKH” or the “Company”) (NYSE: ZKH), a leading maintenance, repair and operations (“MRO”) procurement service platform...
Botox for Gummy Smiles Now Available In Los Angeles at Your Laser Skin Care
Los Angeles, Aug. 07, 2024 (GLOBE NEWSWIRE) — Los Angeles, California – Your Laser Skin Care has announced an exciting expansion to include treatments specifically...
Hair Color Spray Market Size to Surpass US$ 4035.15 Million by 2033, The Brainy Insights
The hair color spray market is thriving, driven by a surge in demand for easy and temporary hair color solutions. Asia Pacific emerged as the...
Breakthrough Study Reveals Molecular Subtypes of Down Syndrome, Offering Insights for Personalized Medicine Approaches
Denver, Aug. 07, 2024 (GLOBE NEWSWIRE) — Global Down Syndrome Foundation (GLOBAL) is proud to support a new study published in Nature Communications by researchers at its...
Waldencast Announces Participation in the Canaccord Genuity 44th Annual Growth Conference
WHITE PLAINS, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) — Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today...
Elutia Announces Second Quarter 2024 Results
Launch Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position Solidified SILVER SPRING, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT)...
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm,...
FibroBiologics Files 2024 Second Quarter Report
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development...
CENTOGENE Receives Delisting Notice From Nasdaq
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) — Centogene N.V., the essential life science partner for data-driven answers in rare...
ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization
PLEASANTON, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) — ProSomnus Sleep Technologies (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced record revenues for...